ferucarbotran

Ferucarbotran is a superparamagnetic iron oxide nanoparticle contrast agent coated with carboxydextran. It is used as an organ-specific MRI contrast agent for the detection and characterization of focal liver lesions. The nanoparticles are phagocytosed by cells of the reticuloendothelial system (RES), primarily in the liver and spleen. This uptake leads to a decrease in signal intensity of normal liver parenchyma on T2- and T1-weighted MRI images, thereby enhancing the contrast between healthy tissue and lesions that do not contain RES cells (such as most malignant tumors). Ferucarbotran significantly improves sensitivity for detecting hypovascular focal liver lesions compared to unenhanced imaging or other modalities like CTAP. It can be administered as an intravenous bolus injection, allowing immediate imaging and reducing examination time. The compound has demonstrated a favorable safety profile in clinical trials[1][4][6][8].

Brand names

ResovistFerrixanCliavist

Other names

ferucarbotran (JAN/USAN)